See you in 2023!
IT'S A WRAP, THANKS FOR JOINING US IN AMSTERDAM
The European Summit on Pharma and Biotech Patent Litigation took place and was a huge success, with over 150 members of the IP community joining together in 2 days of riveting discussion and interactive sessions.
The event proved to be a key opportunity for professionals working in Intellectual Property law, Patent Strategist, Senior Counsel, or IP to meet, share innovations and benchmark success. We can't wait for 2023 to deliver another exciting agenda to the community.
Stay tuned for pictures of the live event.
Our 2022 Programme Delivered:
① Crucial insights on risk-avert, cost-efficient patent litigation strategies
② Tools to differentiate how your company maximises its ROI on patent rights and IP protection.
③ Methods to successfully defend post-filing patent litigation challenges
④ A unique and targeted networking and relationship building platform
Life Sciences Patent Advisory Board
Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.
Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.
Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.
Karine Crepin
Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.
Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.
Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.
Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).
Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”
Fredrick Fredh
Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).
Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Lorenz Kallenbach
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.
Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.
Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Mathilde Rauline
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Register Your Interest for 2023
OUR AUDIENCE
2022 Speakers
Dominic Adair
Rainer Becker
Dr Martijn de Lange
Sven Bostyn
Sara Burghart
Robert Cerwinski
Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr. Cerwinski holds a Master of Science Degree in molecular biology and has a deep understanding of the science, business and regulation of biopharma product development, manufacture and marketing. Mr. Cerwinski co-founded the industry-leading biosimilars practice at Goodwin Procter LLP and is a recognized global authority on biosimilars. He is Senior Editor of the leading legal treatise in the field, Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters) and founded Goodwin’s award-winning biosimilars blog, Big Molecule Watch and its companion blog, Big Molecule Watch China. Mr. Cerwinski was named an IAM Global Leader in Intellectual Property Law in 2021 and is ranked in the Gold Tier of the IAM Patent 1000.
Brian Coggio
Katie Coltart
Kristin Cooklin
Mike Cottler
Ricardo Dijkstra
Robin Ellis
Jules Fabre
Fredrick Fredh
Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).
Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”
Katherine A. Helm
Matt Hervey
Sir Robin Jacob
Rieke Kaup
Stephan Kutik
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.
Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Daan De Lange
Alexander de Leeuw
Alexander de Leeuw is an experienced lawyer specialising in national and international patent litigation.
He frequently litigates before the Dutch courts as well as the European Patent Office. Some examples of cases that Alexander worked on concern CRISPR-Cas9 (Broad/MIT/Harvard), pemetrexed (Sandoz), lithography machines (Carl Zeiss), and surgical laser systems (Alcon).
He also regularly deals with and teaches about the protection of trade secrets, and has been involved in high-profile international trade secret litigation.
Tessa M. Malmund-Cohen
Ewan Nettleton
Arvid van Oorschot
Jason Rice
Roberto Romandini
Adrian Spillman
Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.
His areas of expertise include protection of prophylactics, therapeutics, and diagnostics for infectious diseases, immunological disorders, cancerous diseases, neurodegenerative disorders and metabolic disorders, vaccine technologies, antibody technologies, production of biological and chemical compounds, new medical uses, and formulations of known compounds.
After earning his Ph.D. at the University of Zurich, Switzerland, Adrian was a Consultant at Deloitte, followed by a 7-year stay in various positions in the patent department at Novartis. Furthermore, Adrian was Senior Patent Attorney at Ablynx, an antibody company in Belgium, for three years.
Adrian is a European and Swiss-registered patent attorney and received his LLM from the University of Law in London.
Corinna Sundermann
Craig Svoboda
Otto Swens
Cecil Teles
Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.
Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.
Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.
Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.
Dean Thomas
An experienced life sciences IP lawyer with more than 20 years of experience in house and private practice, throughout Europe.
Nitika Gupta Fiorella
Frantzeska Papadopoulou
Gregory Bacon
Mark van Gardingen
Andras Kupecz
Dr. Inga-Marlene
Tjibbe Douma
Stephan Neuhaus
2022 PARTNERS
Event Partners
Quay Pharma
Quay are world known experts in formulation development and clinical manufacturing of live biotherapeutic dosage forms.
No other CDMO has the breadth of knowledge in the formulation services we offer, our clinical trials manufacturing and supply know how as well as our specialist knowledge in providing cost efficient engineering solutions to meet the many challenges that we know can accompany the finished product manufacture of microbial therapies.
Twenty years of focused know how on formulation and analytical development to meet the demands of global regulatory authorities at all clinical phases, has established Quay Pharma as a leading innovator in the fast growing microbial therapies space. We work with bacteria including fastidious anaerobes, multi-species consortia, viruses including bacteriophages and viral vectors and microbially derived drug products such as recombinant peptides and spores. This diversity requires a broad range of expertise, analytical techniques, operational flexibility and handling requirements to ensure safe and efficacious manufacture specifically during manufacturing scaleup for clinical supply.
We are fully licensed for handling BS class 1 and 2 strains as well genetically modified microorganisms. Quay is able to support your GMP manufacture in Europe and is extending this capability to its new facility in the US.
Unlike other CDMO’s Quay offers a specific formulation route that meets your target profile requirements. We know, from experience, that off the shelf solutions, such as intrinsically enteric capsules do not always work and certainly can not provide the protection to your therapeutics potency that other formulation options do.
Get in touch, we look forward to discussing a bespoke solution to meet your therapeutic needs.
Associate Partners
Session Partners
Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
Workshop Sponsor
Media Partners
Global Legal Group
Website: https://iclg.com/
ICLG.com is a global resource for legal reference, analysis, and news, hosting an array of comprehensive comparative legal guides and research tools that cover law in more than 150 jurisdictions across 50 practice areas.
ICLG.com also provides daily legal news and event directories. At the heart of ICLG.com is an international network of legal experts, whose knowledge and experience are highly valued by legal and business professionals around the world.
CEE Legal Matters
Website: https://ceelegalmatters.com/
Please visit our website for more information.JUVE
Website: https://www.juve-patent.com
JUVE has been reporting on the UPC, the European Patent Office and developments at law firms and in-house departments for twenty years – and in English since 2018.
JUVE Patent provides daily news coverage, in-depth reports and annual rankings on the four most important European patent markets.
The Life Sciences Intellectual Property Review
Website: https://www.lifesciencesipreview.com/
LSIPR (Life Sciences IP Review) is the leading publication that is 100% dedicated to covering the latest IP, Regulatory and Transactional matters in the fields of Life Sciences, Biotechnology and Pharmaceuticals.
With magazines targeted around key industry events, daily online news updates and weekly and monthly digital reports, it is the most comprehensive news and comment service for life sciences professionals across the globe.
Become a Partner
Kisaco Research provides the platform where industry executives can network, learn and meet potential industry partners.
Far from the typical ‘meet-and-greet’ experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand.
Your partnership with Kisaco Research will offer you a strategic approach that is an extension and enhancement of your own marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets.
Find out more by calling us at +44 (0)20 3696 2920 or email [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.